Нусинерсен

Нусинерсен
Систематско (IUPAC)
	all-P-ambo-2’-O-(2-Methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)guanosine
Клинички податоци
Заштитени имиња	Spinraza
AHFS/Drugs.com	Multum Consumer Information
Licence data	EMA:[[[:Предлошка:Infobox drug/EMA-EPAR]] врска]
Начин на издавање	US: само ℞ ;
Начин на; примена	Injection into cerebrospinal fluid
Фармакокинетички податоци
Метаболизам	Exonuclease (3’- and 5’)-mediated hydrolysis
Полувреме на елиминација	135–177 days (in CSF), 63–87 days (in plasma)
Назнака
CAS-број	1258984-36-9
ATC код	M09AX07
DrugBank	DB13161
ChemSpider	34983394
UNII	5Z9SP3X666
KEGG	D10881
Синоними	IONIS-SMNRx, ISIS-SMNRx
Хемиски податоци
Формула	C234H323N61Na17O128P17S17
Моларна маса	7501 Da
	SMILES Cc1cn(c(=O)[nH]c1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)n4cc(c(nc4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)n6cnc7c6ncnc7N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)n9cc(c(nc9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)O)OCCOC ;

Нусинерсен (INN),^[1] со заштитено име Спинраза,^[3] е лек кој се користи во третманот на спинална мускулна атрофија (СМА),^[4] ретко невромускулно нарушување. Во декември 2016 година, стана првиот одобрен лек за третман на ова заболување. Нусинерсенот во САД и ЕУ има ознака лек-сирак.^[5]

Наводи

↑ ^1,0 ^1,1 „International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74“ (PDF). World Health Organization. стр. 413–14. Посетено на 13 March 2017.
↑ ^2,0 ^2,1 Грешка во наводот: Погрешна ознака <ref>; нема зададено текст за наводите по име USlabel2016.
↑ „Nusinersen“. AdisInsight. Посетено на 1 January 2017.
↑ Ottesen, Eric W. (2017-01-01). „ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy“. Translational Neuroscience (англиски). 8 (1): 1–6. doi:10.1515/tnsci-2017-0001. ISSN 2081-6936. PMC 5382937. PMID 28400976.
↑ „Nusinersen“. UK Specialist Pharmacy Service. Архивирано од изворникот на 2019-04-13. Посетено на 31 December 2016.

[INN-1] 1,0 ^1,1 „International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74“ (PDF). World Health Organization. стр. 413–14. Посетено на 13 March 2017.

[USlabel2016-2] 2,0 ^2,1 Грешка во наводот: Погрешна ознака <ref>; нема зададено текст за наводите по име USlabel2016.

[Adis-3] „Nusinersen“. AdisInsight. Посетено на 1 January 2017.

[4] Ottesen, Eric W. (2017-01-01). „ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy“. Translational Neuroscience (англиски). 8 (1): 1–6. doi:10.1515/tnsci-2017-0001. ISSN 2081-6936. PMC 5382937. PMID 28400976.

[5] „Nusinersen“. UK Specialist Pharmacy Service. Архивирано од изворникот на 2019-04-13. Посетено на 31 December 2016.

[1]

[3]

[4]

[5]

[2]

Систематско (IUPAC)

all-P-ambo-2’-O-(2-Methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’→5’)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’→5’)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’→5’)-2’-O-(2-methoxyethyl)guanosine^[1]
Клинички податоци
Заштитени имиња	Spinraza
AHFS/Drugs.com	Multum Consumer Information
Licence data	EMA:[[[:Предлошка:Infobox drug/EMA-EPAR]] врска]
Начин на издавање	US: само ℞
Начин на примена	Injection into cerebrospinal fluid
Фармакокинетички податоци
Метаболизам	Exonuclease (3’- and 5’)-mediated hydrolysis
Полувреме на елиминација	135–177 days (in CSF), 63–87 days (in plasma)

Назнака
CAS-број	1258984-36-9
ATC код	M09AX07
DrugBank	DB13161
ChemSpider	34983394
UNII	5Z9SP3X666^Ок
KEGG	D10881
Синоними	IONIS-SMN_Rx, ISIS-SMN_Rx
Хемиски податоци
Формула	C₂₃₄H₃₂₃N₆₁Na₁₇O₁₂₈P₁₇S₁₇^[2]
Моларна маса	7501 Da^[2]
SMILES Cc1cn(c(=O)[nH]c1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)n4cc(c(nc4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)n6cnc7c6ncnc7N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)n9cc(c(nc9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1ncnc2N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(nc1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cc(c(=O)[nH]c1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)n1cnc2c1nc([nH]c2=O)N)OCCOC)O)OCCOC